Lymphoma

The addition of tafasitamab-cxix to lenalidomide and rituximab improved outcomes for patients with relapsed or refractory follicular lymphoma, according to the agent’s manufacturer.

The European Medicines Agency Committee for Medicinal Products for Human Use has recommended the launch of proposed biosimilar rituximab candidate Ituxredi, Dr. Reddy’s Laboratories announced in a press release.

Patients with acne who used benzoyl peroxide products did not have a risk for malignancy or increased blood benzene levels, according to a pair of studies published in the Journal of the American Academy of Dermatology.

New interim results showed that HyBryte treatment demonstrated positive outcomes in patients with early-stage cutaneous T-cell lymphoma, according to a Soligenix press release.

The FDA granted accelerated approval to epcoritamab-bysp for the treatment of adults with relapsed or refractory follicular lymphoma who have received two or more previous lines of therapy.

A simultaneous, multidrug, multi-targeted treatment regimen produced remissions in patients with certain types of relapsed or refractory diffuse large B-cell lymphoma in a phase 1b/phase 2 study.

Having a tattoo was associated with a 21% increased risk for lymphoma, but more research is needed to better understand the possible connection, according to experts.

Eliza Hawkes, MD, has been named the new chief clinical research officer at Olivia Newton-John Cancer Research Institute.

CHICAGO — Treatment of with an investigational chimeric antigen receptor T-cell therapy showed an acceptable safety profile and produced durable remissions among certain patients with non-Hodgin lymphoma.

Satish Gopal, MD, MPH, feels honored to receive this year’s ASCO Humanitarian Award.